Only one class of chemotherapy, namely taxanes, is effective against prostate cancer, the second leading cause of cancer for men in the United States. A study published online this week (January 17th) in Clinical Cancer Research, researchers have found that a newer member of the taxane family called cabazitaxel, an FDA approved drug, has properties that could make it more effective for some patients - a hypothesis currently being tested in clinical trials. Researchers ...
No comments:
Post a Comment